Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Prime Medicine, Inc. ( (PRME) ) has issued an update.
On March 3, 2026, Prime Medicine reported full-year 2025 financial results and outlined progress across its Prime Editing pipeline, highlighting liver-focused in vivo gene editing programs for Wilson disease and Alpha-1 antitrypsin deficiency, with investigational filings planned for the first half and mid-2026 and initial clinical data expected in 2027. The company also emphasized encouraging Phase 1/2 data for PM359 in chronic granulomatous disease published in December 2025, ongoing FDA engagement toward a potential Biologics License Application, advancement of a cystic fibrosis program and CAR-T collaborations, and a year-end 2025 cash position of $191.4 million that management expects will fund operations into 2027 despite a net loss of $201.1 million.
Prime Medicine’s 2025 results showed R&D expenses rising to $160.6 million and G&A costs increasing modestly to $52.3 million, reflecting continued investment in its in vivo liver franchise and platform while deprioritizing its CGD program and reducing R&D headcount. The combination of robust early clinical data, a diversified development portfolio and a cash runway into 2027 positions the company to seek accelerated approval for PM359 and to strengthen its standing in the competitive gene editing field, though sustained losses underscore ongoing execution and financing risk for investors and partners.
The most recent analyst rating on (PRME) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Prime Medicine, Inc. stock, see the PRME Stock Forecast page.
Spark’s Take on PRME Stock
According to Spark, TipRanks’ AI Analyst, PRME is a Neutral.
The score is held back primarily by weak financial performance (large ongoing losses, negative gross profit, and significant cash burn alongside rising debt). Technicals are mixed but slightly improved near-term, valuation is constrained by negative earnings, and the recent strategy update provides a moderate positive offset due to clearer development timelines and partnership emphasis.
To see Spark’s full report on PRME stock, click here.
More about Prime Medicine, Inc.
Prime Medicine, Inc., based in Cambridge, Mass., is a biotechnology company developing next-generation gene editing therapies using its proprietary Prime Editing platform. The company focuses on one-time, potentially curative treatments across hematology, immunology and oncology, as well as genetic diseases of the liver and lung, targeting indications with well-understood biology and clear regulatory paths.
Average Trading Volume: 3,364,666
Technical Sentiment Signal: Buy
Current Market Cap: $841.2M
For a thorough assessment of PRME stock, go to TipRanks’ Stock Analysis page.